|
| 37740924 | ATN cerebrospinal fluid biomarkers in dementia with Lewy bodies: Initial results from the United States Dementia with Lewy Bodies Consortium. | Alzheimers Dement | 2024 |
| 36449413 | Lecanemab in Early Alzheimer's Disease. | N Engl J Med | 2023 |
| 37718812 | Type 2 Diabetes Comorbidity and Cognitive Decline in Patients with Alzheimer's Disease. | J Alzheimers Dis | 2023 |
| 35574992 | Unmet needs in the diagnosis and treatment of Parkinson's disease psychosis and dementia-related psychosis. | Int J Psychiatry Clin Pract | 2023 |
| 36949897 | ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease. | Alzheimers Dement (N Y) | 2023 |
| 37410252 | Correction to: Screening, Diagnosis, and Management of Parkinson's Disease Psychosis: Recommendations From an Expert Panel. | Neurol Ther | 2023 |
| 37071794 | Cerebral white matter rarefaction has both neurodegenerative and vascular causes and may primarily be a distal axonopathy. | J Neuropathol Exp Neurol | 2023 |
| 36749830 | Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease. | Expert Opin Investig Drugs | 2023 |
| 36873923 | Listening session with the US Food and Drug Administration, Lewy Body Dementia Association, and an expert panel. | Alzheimers Dement (N Y) | 2023 |
| 36599073 | Response to: Multiple Cerebral Hemorrhages in a Patient Receiving Lecanemab and Treated with t-PA for Stroke. | N Engl J Med | 2023 |
| 36627511 | Biomarker-based diagnosis of preclinical Alzheimer disease: time for the clinic? | Nat Rev Neurol | 2023 |
| 35026040 | Primary prevention recommendations to reduce the risk of cognitive decline. | Alzheimers Dement | 2022 |
| 35841240 | The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report. | J Prev Alzheimers Dis | 2022 |
| 35841239 | Tackling a Major Deficiency of Diversity in Alzheimer's Disease Therapeutic Trials: An CTAD Task Force Report. | J Prev Alzheimers Dis | 2022 |
| 35697056 | The importance of genomics in advancing the diagnosis and treatment of dementia. | Lancet Neurol | 2022 |
| 35532913 | Safety, Tolerability, and Immunogenicity of the ACI-24 Vaccine in Adults With Down Syndrome: A Phase 1b Randomized Clinical Trial. | JAMA Neurol | 2022 |
| 35386473 | Role of tau deposition in early cognitive decline in Down syndrome. | Alzheimers Dement (Amst) | 2022 |
| 36517479 | Optimal deep brain stimulation sites and networks for stimulation of the fornix in Alzheimer's disease. | Nat Commun | 2022 |
| 36003033 | COR388 (atuzaginstat): an investigational gingipain inhibitor for the treatment of Alzheimer disease. | Expert Opin Investig Drugs | 2022 |
| 36339394 | Review of Advanced Drug Trials Focusing on the Reduction of Brain Beta-Amyloid to Prevent and Treat Dementia. | J Exp Pharmacol | 2022 |
| 35906500 | Screening, Diagnosis, and Management of Parkinson's Disease Psychosis: Recommendations From an Expert Panel. | Neurol Ther | 2022 |
| 36031683 | Neuropathologic validation of the Alzheimer's Questionnaire. | Aging Clin Exp Res | 2022 |
| 35319142 | Longitudinal Assessment of Intravoxel Incoherent Motion Diffusion-Weighted MRI Metrics in Cognitive Decline. | J Magn Reson Imaging | 2022 |
| 35173668 | Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium. | Front Neurol | 2022 |
| 35111361 | The Cause of Alzheimer's Disease: The Theory of Multipathology Convergence to Chronic Neuronal Stress. | Aging Dis | 2022 |
| 33480187 | Brain structures and networks responsible for stimulation-induced memory flashbacks during forniceal deep brain stimulation for Alzheimer's disease. | Alzheimers Dement | 2021 |
| 33905474 | Mapping autonomic, mood and cognitive effects of hypothalamic region deep brain stimulation. | Brain | 2021 |
| 33899637 | Dementia with Lewy bodies: emerging drug targets and therapeutics. | Expert Opin Investig Drugs | 2021 |
| 33551954 | Early Stages of Alzheimer's Disease: Evolving the Care Team for Optimal Patient Management. | Front Neurol | 2021 |
| 33720879 | Clinicopathological Correlation: Dopamine and Amyloid PET Imaging with Neuropathology in Three Subjects Clinically Diagnosed with Alzheimer's Disease or Dementia with Lewy Bodies. | J Alzheimers Dis | 2021 |
| 34643892 | Editorial: A Time of Transition of Alzheimer's Disease in the Advent of Anti-Amyloid Monoclonal Antibodies. | Neurol Ther | 2021 |
| 34796262 | Is diabetes associated with increased pathological burden in Alzheimer's disease? | Alzheimers Dement (Amst) | 2021 |
| 34101796 | Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021. | J Prev Alzheimers Dis | 2021 |
| 34182407 | Neurofibrillary tau depositions emerge with subthreshold cerebral beta-amyloidosis in down syndrome. | Neuroimage Clin | 2021 |
| 34151817 | Effect of Age on Clinical Trial Outcome in Participants with Probable Alzheimer's Disease. | J Alzheimers Dis | 2021 |
| 33933186 | Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. | Lancet Neurol | 2021 |
| 34095437 | Intepirdine as adjunctive therapy to donepezil for mild-to-moderate Alzheimer's disease: A randomized, placebo-controlled, phase 3 clinical trial (MINDSET). | Alzheimers Dement (N Y) | 2021 |
| 33981957 | Does Informant-Based Reporting of Cognitive Decline Correlate with Age-Adjusted Hippocampal Volume in Mild Cognitive Impairment and Alzheimer's Disease? | J Alzheimers Dis Rep | 2021 |
| 34110536 | Critical Appraisal of Amyloid Lowering Agents in AD. | Curr Neurol Neurosci Rep | 2021 |
| 33971962 | Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. | Alzheimers Res Ther | 2021 |
| 33458891 | Practical recommendations for timely, accurate diagnosis of symptomatic Alzheimer's disease (MCI and dementia) in primary care: a review and synthesis. | J Intern Med | 2021 |
| 33455481 | Therapeutic considerations for APOE and TOMM40 in Alzheimers disease: A tribute to Allen Roses MD. | Expert Opin Investig Drugs | 2021 |
| 33368017 | Potential Neuroregenerative and Neuroprotective Effects of Uridine/Choline-Enriched Multinutrient Dietary Intervention for Mild Cognitive Impairment: A Narrative Review. | Neurol Ther | 2021 |
| 33135288 | Open Peer Commentary to "Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019". | Alzheimers Dement | 2021 |
| 32320406 | Severe hyposmia distinguishes neuropathologically confirmed dementia with Lewy bodies from Alzheimer's disease dementia. | PLoS One | 2020 |
| 31706733 | The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis. | Alzheimers Dement | 2020 |
| 32034933 | Neuropathological Findings in Parkinson's Disease With Mild Cognitive Impairment. | Mov Disord | 2020 |
| 31879235 | Effects of a combined transcranial magnetic stimulation (TMS) and cognitive training intervention in patients with Alzheimer's disease. | Alzheimers Dement | 2020 |
| 33304988 | APOE ε4/ε4 homozygotes with early Alzheimer's disease show accelerated hippocampal atrophy and cortical thinning that correlates with cognitive decline. | Alzheimers Dement (N Y) | 2020 |
| 33036984 | Alzheimer's disease beyond amyloid: strategies for future therapeutic interventions. | BMJ | 2020 |